Ainos, Inc. - AIMD STOCK NEWS

Ainos, Inc. (NASDAQ:AIMD) has received Institutional Review Board (IRB) approval from the National Taiwan University Hospital for its clinical trial on VELDONA®, a low-dose oral interferon formulation for treating oral warts in HIV-positive patients. The trial, involving 40 participants, will evaluate VELDONA®'s efficacy in combination with antiretroviral therapy. VELDONA® has received orphan drug designation from the FDA, highlighting its potential in addressing an unmet medical need.

The next step is obtaining approval from the Taiwan Food and Drug Administration (TFDA). The application was submitted on August 28, 2024. The Site Initiation Visit is expected in November 2024, with patient enrollment lasting one year. The study is anticipated to conclude by July 2026.

Ainos, Inc. (NASDAQ:AIMD) has been featured in a Water Tower Research report highlighting its upcoming VELDONA® clinical study for Sjogren's syndrome, set to begin in December 2024 in Taiwan. The study will enroll 24 patients to assess VELDONA®'s effectiveness in reducing dryness symptoms over 24-48 weeks. Key points include:

1. Taiwan FDA approval expected by November 2024
2. Trial projected to complete by January 2026
3. Primary endpoint: improvement of saliva secretion and dryness symptoms
4. Secondary endpoints: ESSPRI, ESSDAI, VAS, and salivary gland function
5. Sjogren's syndrome affects up to 1% of the global population
6. Previous U.S. Phase 3 data showed significant improvements

This study follows Ainos' capital-efficient strategy of conducting clinical trials in Taiwan, with a prior VELDONA study for oral warts in HIV+ patients planned for November 2024.

Ainos (NASDAQ:AIMD) has announced plans to conduct a Taiwan clinical study for VELDONA in treating Sjögren's syndrome, a rare autoimmune disease. The study, to be conducted at Taipei Medical University-Shuang Ho Hospital, aims to recruit 24 patients who will take three sublingual VELDONA tablets daily for 24-48 weeks. The primary objective is to evaluate VELDONA's efficacy in improving saliva secretion and dryness symptoms.

The company has previously conducted eight clinical trials in the U.S., including three Phase 3 studies that showed positive benefits in increasing unstimulated whole saliva secretion without significant adverse effects. Ainos expects to complete all regulatory approvals for the Taiwan study by November 2024, with patient enrollment lasting approximately six months. The study is projected to conclude in January 2026.

Ainos, Inc. (NASDAQ:AIMD) has announced a new clinical trial for VELDONA®, its low-dose oral interferon-alpha formulation, to treat oral warts in HIV+ patients on antiretroviral therapy. Water Tower Research has issued a report highlighting key aspects of this upcoming trial:

1. The single-site, double-blind study will commence at the National Taiwan University Hospital by November 2024.

2. The trial will enroll 40 subjects, randomized 3:1 to VELDONA® or placebo.

3. The primary endpoint is a 75% reduction in oral wart surface area over 24 weeks.

4. VELDONA® has received Orphan Drug Designation from the FDA for this indication.

5. The study aligns with Ainos' capital-efficient strategy, as clinical studies in Taiwan are less costly than in the U.S.

6. There are currently no approved therapeutics for oral warts, which affect approximately 49,000 HIV+ patients in the U.S.

Ainos (NASDAQ:AIMD) has announced plans to initiate a clinical study for VELDONA, a low-dose oral interferon-alpha formulation, as a potential treatment for oral warts in HIV-positive patients. The study will be conducted at National Taiwan University Hospital, involving 40 participants in a double-blind trial lasting 24 weeks. VELDONA has received Orphan Drug Designation from the U.S. FDA for this indication.

The study aims to evaluate the efficacy of VELDONA in reducing oral wart surface area, with a successful response defined as a 75% or greater reduction. Previous U.S. trials involving 77 HIV-positive patients showed significant reductions in oral wart surface area, with decreases of over 75% and up to 99% in some cases. The study is expected to begin in November 2024 and conclude in July 2026.

Ainos (NASDAQ:AIMD) has secured a Taiwan invention patent for VELDONA®, its breakthrough formulation for coronavirus treatment and prevention. The company has also filed for global patent protection under the Patent Cooperation Treaty (PCT). VELDONA® utilizes an advanced oral rapid-dissolving tablet technology that enhances immune system function and reduces the risk of coronavirus infections.

Key highlights:

• VELDONA® shows potential in activating the immune system against various coronavirus variants and preventing new infections
• The technology may extend to other viral diseases, including Hepatitis B, HIV, and various animal viruses
• Ainos believes VELDONA® could become a competitive, comprehensive antiviral therapy due to its high efficacy, safety, and low side effects

Ainos (NASDAQ: AIMD, AIMDW), a healthcare company specializing in AI-powered point-of-care testing and VELDONA low-dose interferon therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place both in-person at the Lotte New York Palace Hotel and virtually on September 9-10, 2024.

Key highlights:

• Ainos will conduct one-on-one meetings during the conference
• Mr. Jack Lu, Director of Corporate Development, will deliver a live presentation on September 10, 2024, at 4 p.m.
• The company invites shareholders and interested parties to learn about their journey towards becoming 'AI's nose' capable of digitizing smell
• Interested attendees can register for the conference through the HCW Events website

Ainos, Inc. (NASDAQ:AIMD) is making significant strides in AI-powered smell digitization technology. CEO Chun-Hsien Tsai highlighted key achievements and upcoming milestones in a shareholder letter:

1. AI Nose Technology: Ainos is developing AI-powered digital nose sensors for healthcare and smart factories.

2. Healthcare Applications: The next-gen Ainos Flora, targeting women's health and STI testing, is set for clinical trials in Q4 2024.

3. Elderly Care: Collaborating with Nisshinbo Micro Devices and Taiwan Inabata Sangyo, Ainos aims for pilot production in Q4 2024.

4. Smart Factories: AI Nose achieved 79% accuracy in identifying VOCs in semiconductor factories, with pilot production ready in Q4 2024.

5. IP Portfolio: Ainos secured exclusive licenses for 10 multi-region patents related to gas sensors and medical device technologies.

Ainos (NASDAQ: AIMD) has unveiled a breakthrough in its AI Nose technology, achieving 79% accuracy in identifying 761 samples across 22 volatile organic compounds (VOCs) in Japanese semiconductor manufacturing factories. This advancement significantly enhances smart manufacturing factory automation and safety. The AI Nose can detect manufacturing process contamination, ensure health and safety, prevent fires, and optimize gas sensing with real-time feedback.

Ainos plans to integrate AI Nose into smart factory robotics systems, equipping robots with a human-like sense of smell to improve collaboration with workers and enhance safety. This development expands AI Nose's applications beyond medical uses into the industrial sector, positioning Ainos as a leader in VOC sensing technology.